Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal
Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...
Wedbush Forecasts Biogen’s FY2024 Earnings (NASDAQ:BIIB)
Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...
24/7 Wall St. on MSN8d
Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street Expert
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
Seeking Alpha25d
Biogen Holds On, But Growth Slips Through Its Fingers
There has also been a shift in treatment preferences over the years in MS towards B-cell depleting therapies like Roche's (OTCQX:RHHBY) Ocrevus (Biogen earned $346.8 million in Q3 from Ocrvus ...
Wedbush Weighs in on Biogen’s Q4 Earnings (NASDAQ:BIIB)
Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...
Yahoo Finance22d
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ 100 stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money ...
pharmaphorum2d
Dangerous inflammation prompts worldwide withdrawal of MS drug
Biogen and AbbVie have announced the voluntary ... This includes those who experience highly active relapsing MS despite having undergone a full and adequate course of treatment with at least ...
Yahoo Finance28d
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges
Biogen’s top-line remains heavily reliant on its multiple sclerosis (MS) portfolio, which accounts for over 60% of 2024 revenue, including royalties from Ocrevus. Piper Sandler flagged several ...
Insider Monkey21d
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
“Third, Biogen’s been running on fumes while it works on its Alzheimer’s drug, but the fumes, basically a very good MS drug, in a crowded field, aren’t enough. Not with the unmet projectio ...
Biogen’s Hold Rating: Navigating Challenges in Alzheimer’s Treatments and Pipeline Development
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...
pharmaphorum2d
FDA slaps partial hold on Biogen, InnoCare MS drug
Some neurologists have even started talking about the possibility that the drugs could not only slow down progression of MS, but even potentially offer a functional cure. Biogen licensed rights to ...